RE: Turner Pope23 Feb 2021 18:52
I like this bit at the end of crumbs original post
"the contrasting ‘US approach’ adopted by Redmile instead, is to inject significant ‘transformational’ cash
funding (in either straight equity, CLNs or a mix of the two) that can be rapidly put to work in order to resource and
accelerate existing programmes, while also seeking to seize opportunities unique technologies might present and
in tandem broadening pipelines sufficiently to capture a larger proportion of the inherent value, rather than
externalise the assets too early through royalty or milestone-based sales to larger, better-resourced development
partnerships. "
This applies particularly to the Glycans mAbs and Avidimab for which Scancell were preparing to do an early deal with one of their collaborators.
I refer my learned friends to the AGM presentation 22mins 55 secs to 25 mins and also 26 mins to 28 mins.
https://www.youtube.com/watch?v=VEbic53pJ_A
This looks like a pretty good pipeline on its own without considering Scancell's 2 main platforms of Immunobody and Moditope.